Products

BrainScope TBI
BrainScope Company
Clinical Decision Support & Reference
BrainScope TBI is an FDA-cleared, AI-powered EEG device for rapid, objective assessment of mild traumatic brain injury (mTBI), including concussions and brain bleeds, designed to reduce unnecessary head CTs at the point of care.
Ahead 300
BRAINSCOPE COMPANY
Neurology AI
The Ahead 300 (commercialized as BrainScope One) is an FDA-cleared, AI-powered medical device that uses EEG to objectively assess traumatic brain injury, including concussions and brain bleeds, at the point of care.
BrainScope Ahead 100
BRAINSCOPE COMPANY
Neurology AI
BrainScope Ahead 100 is an FDA-cleared, AI-powered EEG device for rapid, non-invasive assessment of mild traumatic brain injury (mTBI), including concussions and brain bleeds, designed to reduce unnecessary CT scans.

See all 4 products →

About BRAINSCOPE COMPANY

BrainScope Company is a leading medical neurotechnology firm that leverages AI and machine learning with electroencephalographic (EEG) data to provide objective diagnostic insights for brain health. Their initial commercial product is an FDA-cleared, non-invasive, handheld device designed to assess mild traumatic brain injury (mTBI), including both structural injuries (like brain bleeds) and functional injuries (like concussions), at the point of care. This technology aims to reduce unnecessary CT scans and improve patient triage in emergency departments and urgent care settings.

Building on its foundation in TBI assessment, BrainScope is expanding its proprietary platform to develop novel biomarkers for a broader range of neurological conditions. Current and emerging focus areas include early Alzheimer’s disease detection, assessment of Amyloid-Related Imaging Abnormalities (ARIA), rapid stroke evaluation, concussion subtyping, military blast exposure, and brain fog. The company’s approach emphasizes rapid, radiation-free, and cost-effective solutions that transform traditional EEG data into clinically actionable insights, aiming to redefine brain health management across acute care, drug development, and consumer health.

Focus Areas

Traumatic Brain Injury (TBI) assessment mild Traumatic Brain Injury (mTBI) assessment concussion diagnosis brain bleed detection Alzheimer's disease prediction stroke evaluation ARIA assessment EEG analysis AI/machine learning in neurology biomarker development

Business Intelligence

Key InvestorsRevolution LLC, DBL Partners, Maryland Venture Fund, ZG Ventures, Alzheimer's Drug Discovery Foundation (ADDF), Aon, Bruin Capital, GE Aerospace
PartnershipsUnited States Department of Defense, General Electric, National Football League (NFL), NYU School of Medicine, Johns Hopkins University, Emory University, University of Virginia, Washington University in St. Louis, Prevacus, Yankee Alliance, Vizient, Tri-anim Health Services
AcquisitionsNone
TechnologyAI-powered EEG platform, advanced machine learning and deep learning, Large Neural Model platform, cloud-native analytics, disposable electrode headset, mobile-device interface, digital signal processing
FDA Clearances8 cleared products (estimated)

What Physicians Need to Know

TBI & Concussion Management
Specializes in comprehensive assessment for Traumatic Brain Injury (TBI), mild Traumatic Brain Injury (mTBI), and concussion diagnosis, including rapid and accurate brain bleed detection. This offers physicians critical tools for timely intervention and improved patient outcomes in acute neurological events.
Neurodegenerative Disease Prediction
Focuses on the early prediction of Alzheimer's disease, providing physicians with advanced insights to identify at-risk patients sooner, enabling proactive management and potential participation in clinical trials.
Acute Neurological Event Evaluation
Expertise in rapid stroke evaluation and precise ARIA (Amyloid-Related Imaging Abnormalities) assessment, crucial for guiding treatment decisions and monitoring patients undergoing certain Alzheimer's therapies.
Advanced Neuro-Diagnostics
Utilizes sophisticated EEG analysis to provide detailed insights into brain activity, aiding in the diagnosis and monitoring of various neurological conditions beyond traditional imaging.
AI-Driven Neurological Insights
Leverages cutting-edge AI/machine learning in neurology for enhanced diagnostic accuracy, predictive analytics, and personalized treatment recommendations, transforming complex data into actionable clinical intelligence.
Biomarker Development
Innovates in the discovery and validation of novel biomarkers for neurological conditions, offering physicians new tools for objective diagnosis, prognosis, and therapeutic monitoring.
Physician Tip

BRAINSCOPE COMPANY offers a powerful suite of tools for neurologists, emergency physicians, and primary care providers. Leverage their AI-driven assessments for faster, more accurate diagnoses of TBI, mTBI, and stroke, which can significantly impact patient management and reduce diagnostic uncertainty. Utilize their Alzheimer's prediction capabilities for early intervention strategies and patient counseling. The objective data from EEG analysis and novel biomarkers can provide critical support for complex cases and aid in monitoring treatment efficacy. Consider integrating their solutions for a more comprehensive and data-driven approach to neurological care, potentially improving patient outcomes and streamlining clinical workflows.

BRAINSCOPE COMPANY's solutions are designed for seamless integration with existing Electronic Health Record (EHR) systems, Picture Archiving and Communication Systems (PACS), and other hospital information systems. This ensures a unified data flow, reduces manual data entry, and provides physicians with a consolidated view of patient neurological health within their familiar clinical environment. API-driven integration allows for custom workflows and data exchange, enhancing interoperability across diverse healthcare IT infrastructures.

Products by BRAINSCOPE COMPANY

4 products in the directory

BrainScope TBI
BrainScope Company
Clinical Decision Support & Reference
BrainScope TBI is an FDA-cleared, AI-powered EEG device for rapid, objective assessment of mild traumatic brain injury (mTBI), including concussions and brain bleeds, designed to reduce unnecessary head CTs at the point of care.
Ahead 300
BRAINSCOPE COMPANY
Neurology AI
The Ahead 300 (commercialized as BrainScope One) is an FDA-cleared, AI-powered medical device that uses EEG to objectively assess traumatic brain injury, including concussions and brain bleeds, at the point of care.
BrainScope Ahead 100
BRAINSCOPE COMPANY
Neurology AI
BrainScope Ahead 100 is an FDA-cleared, AI-powered EEG device for rapid, non-invasive assessment of mild traumatic brain injury (mTBI), including concussions and brain bleeds, designed to reduce unnecessary CT scans.
Brainscope Ahead 200
BRAINSCOPE COMPANY
Neurology AI
BrainScope Ahead 200 is an FDA-cleared, AI-powered EEG medical device for the adjunctive assessment of mild traumatic brain injury (mTBI) and concussion, designed to reduce unnecessary head CT scans.

Reviews & Opinions

No web reviews on file yet for BRAINSCOPE COMPANY. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about BRAINSCOPE COMPANY.

Loading videos...

Videos load interactively. If none appear, search YouTube for BRAINSCOPE COMPANY →

View all on YouTube

Press & Coverage

Business Wire
BrainScope's EEG-Based Biomarker Predicts Dementia Risk Up to 7 Years Before Initial Diagnosis, Published in Nature Scientific Reports
A peer-reviewed study published in Scientific Reports (Nature Portfolio) demonstrates BrainScope's EEG-based biomarker can identify individuals at risk of cognitive decline 5 to 7 years before diagnosis, reinforcing the company's focus on early dementia detection.
2026-02
BrainScope
BrainScope Strengthens Executive Team with Veteran Commercial Leader David Wingate
BrainScope announced the appointment of David Wingate as Vice President of Sales and Commercial Operations, aiming to strengthen its leadership and accelerate commercial momentum in AI-enabled brain health assessment.
2026-05
BrainScope
BrainScope Expands Advisory Board with Appointment of Six Renowned Neuroscience Leaders
BrainScope expanded its advisory board with six neuroscience leaders to guide the company's growth and adoption of its AI-powered brain health platform.
2026-01
Fierce Biotech
Medtech veteran Matt Adams takes the helm at AI head injury company BrainScope
Matt Adams, a medtech veteran with over 20 years of experience, has been appointed as the new Chief Executive at BrainScope, succeeding Laurie Silver.
2025-11
BrainScope
BrainScope Expands Board and Launches Advanced Deep Learning Platform to Enhance Brain Health Insights
BrainScope launched its next-generation deep learning platform to deliver faster, objective, and clinically actionable insights across various brain health conditions, including concussion, stroke, and early Alzheimer's detection.
2025-06
BrainScope
BrainScope Completes Proof-of-Concept for Groundbreaking Early Alzheimer's Prediction Biomarker
BrainScope successfully completed the proof-of-concept phase for a novel brain activity-based biomarker designed to predict the onset of Alzheimer's disease at its earliest stage.
2024-10
BrainScope
BrainScope Receives Investment from the Alzheimer's Drug Discovery Foundation for Alzheimer's Prediction Biomarker
The Alzheimer's Drug Discovery Foundation (ADDF) invested in BrainScope's Series B equity financing round to support the development of an AI/Machine Learning-derived biomarker for predicting Alzheimer's onset.
2023-09
Business Wire
BrainScope Receives Innovative Technology Contract from Vizient for Its Novel Head Injury Triage Medical Device
BrainScope's FDA-cleared, handheld medical device for mild traumatic brain injury assessment received an Innovative Technology contract from Vizient, Inc., the nation's largest member-driven healthcare performance improvement company.
2022-08

Frequently Asked Questions

BrainScope offers an FDA-cleared point-of-care technology that objectively assesses head-injured patients for both brain bleeds and concussions. Its products include the Structural Injury Classifier (SIC) for brain bleed likelihood and the Brain Function Index (BFI) and Concussion Index (CI) for objective concussion assessment.
BrainScope is a leader in AI-enabled EEG technology, having commercialized the first FDA-cleared AI/machine learning medical device in neurology. Its proprietary platform uses advanced machine and deep learning to analyze EEG data from any source, delivering rapid, radiation-free, and cost-effective biomarkers.
BrainScope is advancing novel biomarkers for early Alzheimer's detection, having successfully completed proof-of-concept for an EEG-based biomarker that predicts dementia risk up to seven years before diagnosis. The company is also developing biomarkers for rapid stroke evaluation and assessing ARIA (Amyloid-Related Imaging Abnormalities) associated with Alzheimer's treatments.
BrainScope's technology provides rapid, objective, and radiation-free assessment of brain bleeds and concussions, typically in under 20 minutes. Its use has demonstrated a significant reduction in unnecessary head CT scans (around 50%) and decreased patient length of stay in emergency departments.
Yes, BrainScope has multiple FDA-cleared biomarkers for head injury assessment, including its initial commercial product for brain bleeds and concussions. The company developed and commercialized the first FDA-cleared AI/machine learning medical device in the field of neurology.
BrainScope's approach involves applying advanced machine and deep learning to EEG data to create objective, non-invasive, radiation-free, and cost-effective biomarkers. These biomarkers aim to identify disease-relevant features from the earliest signs of dysfunction, supporting precision-driven clinical trials, early diagnosis, and personalized treatment.
While specific pricing details are not publicly available, BrainScope emphasizes that its biomarkers are 'cost-effective' and 'less expensive than standard diagnostic methods such as neuroimaging.' The technology also contributes to cost savings by reducing unnecessary head CT scans and patient length of stay.
BrainScope is a commercial-stage neurotechnology company with over 15 years of experience and a robust patent portfolio. They have secured investment from the Alzheimer's Drug Discovery Foundation (ADDF) and are actively pursuing collaboration partnerships with Alzheimer's-focused drug companies.

Related Companies

Google DeepMind is a leading artificial intelligence (AI) research laboratory, a subsidiary of Alphabet Inc., dedicated to developing advanced AI systems to benefit humanity. The company focuses on creating general-purpose AI that can learn and solve complex problems, drawing inspiration from neuroscience and machine learning. Their work spans various fields, including healthcare, scientific discovery, and […]

TalkToMedi is a Canadian healthcare AI company that has developed a clinical-grade voice AI platform called MEDI. This platform is designed to automate patient communication and administrative tasks for medical clinics, including family medicine, specialty clinics, allied health, and physiotherapy. MEDI handles high-volume patient calls, automating appointment inquiries, booking, rescheduling, and cancellations based on the […]

Menaela is an AI-first practice management system designed for solo practitioners, small private clinics, and clinic owners. It integrates patient communication, scheduling, CRM, and medical documentation into a single platform, aiming to replace multiple disconnected tools and bots. The system features an AI practice manager that understands natural-language requests, utilizes real clinic data, and performs […]

Avie is operated by AVIE TECNOLOGIA LTDA, headquartered in Santo André, São Paulo, Brazil. Avie provides WhatsApp reception in Brazilian Portuguese, appointment scheduling, rescheduling and cancellations through Google Calendar or Feegow, clinic CRM, follow-up messages and an online booking website. Clinic staff can review conversations and take over when human support is needed. Clinic CRM […]

Saile is a physician-founded healthcare technology company that addresses critical inefficiencies in healthcare staffing and credentialing. Their AI-powered platform acts as a “universal credential passport” for physicians, centralizing and managing all medical licenses, certifications, and CME credits in one secure, portable vault. This system aims to significantly reduce the administrative burden and delays associated with […]

Data Capture Experts (DCE) is an Australian-based healthcare AI company that is at the forefront of digital health transformation. They specialize in developing and implementing digital health platforms that integrate data, technology, and human-centered design to create intuitive and connected healthcare systems. Their flagship platform, DC2Vue, is designed to go beyond traditional Electronic Medical Records […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.